Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021). Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—An updated review. Cancers, 13(17), 4287.

Article  PubMed  PubMed Central  Google Scholar 

Vahdanikia, V., Maleki, M., Fam, R. A. I., & Abdi, A. (2022). Assessment the effect of human umbilical cord wharton’s jelly stem cells on the expression of homing genes; CXCR4 and VLA-4 in cell line of breast cancer. International Journal of Hematology-Oncology and Stem Cell Research. https://doi.org/10.18502/ijhoscr.v16i2.9204

Article  PubMed  PubMed Central  Google Scholar 

Maghsoodi, M. S., Khosroshahi, N. S., Beilankouhi, E. A. V., Valilo, M., & Feizi, M. A. H. (2023). VEGF-634G> C (rs2010963) gene polymorphism and high risk of breast cancer in the Northwest of Iran. Indian Journal of Gynecologic Oncology., 21(1), 6.

Article  Google Scholar 

Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., et al. (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clinical cancer research., 10(16), 5367–5374.

Article  CAS  PubMed  Google Scholar 

Garrido-Castro, C. (2019). Insights into molecular classifications of triple-negative breast cancer: Improving patient selection for treatment. Cancer Discovery, 9, 176.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hammerl, D., Martens, J. W., Timmermans, M., Smid, M., Trapman-Jansen, A. M., Foekens, R., et al. (2021). Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. Nature communications, 12(1), 1–13.

Article  Google Scholar 

Lee, K.-L., Kuo, Y.-C., Ho, Y.-S., & Huang, Y.-H. (2019). Triple-negative breast cancer: Current understanding and future therapeutic breakthrough targeting cancer stemness. Cancers, 11(9), 1334.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., et al. (2007). Triple-negative breast cancer: Clinical features and patterns of recurrence. Clinical Cancer Research, 13(15), 4429–4434.

Article  PubMed  Google Scholar 

Ademuyiwa, F. O., Groman, A., O’Connor, T., Ambrosone, C., Watroba, N., & Edge, S. B. (2011). Impact of body mass index on clinical outcomes in triple-negative breast cancer. Cancer, 117(18), 4132–4140.

Article  PubMed  Google Scholar 

Shi, J., Liu, F., & Song, Y. (2020). Progress: Targeted therapy, immunotherapy, and new chemotherapy strategies in advanced triple-negative breast cancer. Cancer Management and Research., 12, 9375.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., et al. (2007). The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clinical Cancer Research, 13(8), 2329–2334.

Article  CAS  PubMed  Google Scholar 

Vaz-Luis, I., Ottesen, R. A., Hughes, M. E., Mamet, R., Burstein, H. J., Edge, S. B., et al. (2014). Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: A multi-institutional study. Journal of Clinical Oncology, 32(20), 2142.

Article  PubMed  PubMed Central  Google Scholar 

Schmid, P., Cortes, J., Dent, R., Pusztai, L., McArthur, H., Kümmel, S., et al. (2022). Event-free survival with pembrolizumab in early triple-negative breast cancer. New England Journal of Medicine, 386(6), 556–567.

Article  CAS  PubMed  Google Scholar 

Sikov, W. M., Polley, M.-Y., Twohy, E., Perou, C. M., Singh, B., Berry, D. A., et al. (2019). CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT)+/-carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC). American Society of Clinical Oncology. https://doi.org/10.1200/JCO.2019.37.15_suppl.591

Article  Google Scholar 

Wang, Z., Peng, H., Shi, W., Gan, L., Zhong, L., He, J., et al. (2021). Application of photodynamic therapy in cancer: Challenges and advancements. Biocell, 45(3), 489.

Article  CAS  Google Scholar 

Conklin, K. A. (2004). Chemotherapy-associated oxidative stress: Impact on chemotherapeutic effectiveness. Integrative Cancer Therapies, 3(4), 294–300.

Article  CAS  PubMed  Google Scholar 

Alavi, M., Farkhondeh, T., Aschner, M., & Samarghandian, S. (2021). Resveratrol mediates its anti-cancer effects by Nrf2 signaling pathway activation. Cancer Cell International, 21(1), 1–9.

Article  Google Scholar 

Ailioaie, L. M., Ailioaie, C., & Litscher, G. (2021). Latest innovations and nanotechnologies with curcumin as a nature-inspired photosensitizer applied in the photodynamic therapy of cancer. Pharmaceutics, 13(10), 1562.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yanovsky, R. L., Bartenstein, D. W., Rogers, G. S., Isakoff, S. J., & Chen, S. T. (2019). Photodynamic therapy for solid tumors: A review of the literature. Photodermatology, Photoimmunology & Photomedicine, 35(5), 295–303.

Article  Google Scholar 

Cheong, T.-C., Shin, E. P., Kwon, E.-K., Choi, J.-H., Wang, K.-K., Sharma, P., et al. (2015). Functional manipulation of dendritic cells by photoswitchable generation of intracellular reactive oxygen species. ACS Chemical Biology, 10(3), 757–765.

Article  CAS  PubMed  Google Scholar 

Hwang, H. S., Shin, H., Han, J., & Na, K. (2018). Combination of photodynamic therapy (PDT) and anti-tumor immunity in cancer therapy. Journal of Pharmaceutical Investigation, 48(2), 143–151.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ozog, D. M., Rkein, A. M., Fabi, S. G., Gold, M. H., Goldman, M. P., Lowe, N. J., et al. (2016). Photodynamic therapy: A clinical consensus guide. Dermatologic Surgery, 42(7), 804–827.

Article  CAS  PubMed  Google Scholar 

Wachowska, M., Muchowicz, A., & Demkow, U. (2015). Immunological aspects of antitumor photodynamic therapy outcome. Central European Journal of Immunology, 40(4), 481–485.

Article  CAS  PubMed  Google Scholar 

Ragusa, A., Centonze, C., Grasso, M. E., Latronico, M. F., Mastrangelo, P. F., Fanizzi, F. P., et al. (2017). Composition and statistical analysis of biophenols in Apulian Italian EVOOs. Foods, 6(10), 90.

Article  PubMed  PubMed Central  Google Scholar 

Gutiérrez-Escobar, R., Aliaño-González, M. J., & Cantos-Villar, E. (2021). Wine polyphenol content and its influence on wine quality and properties: A review. Molecules, 26(3), 718.

Article  PubMed  PubMed Central  Google Scholar 

Khan, J., Deb, P. K., Priya, S., Medina, K. D., Devi, R., Walode, S. G., et al. (2021). Dietary flavonoids: Cardioprotective potential with antioxidant effects and their pharmacokinetic, toxicological and therapeutic concerns. Molecules, 26(13), 4021.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Quarta, A., Gaballo, A., Pradhan, B., Patra, S., Jena, M., & Ragusa, A. (2021). Beneficial oxidative stress-related trans-resveratrol effects in the treatment and prevention of breast cancer. Applied Sciences, 11(22), 11041.

Article  CAS  Google Scholar 

Orallo, F. (2006). Comparative studies of the antioxidant effects of cis-and trans-resveratrol. Current Medicinal Chemistry, 13(1), 87–98.

Article  CAS  PubMed  Google Scholar 

Liang, Z.-J., Wan, Y., Zhu, D.-D., Wang, M.-X., Jiang, H.-M., Huang, D.-L., et al. (2021). Resveratrol mediates the apoptosis of triple negative breast cancer cells by reducing POLD1 expression. Frontiers in Oncology, 11, 569295.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ren, B., Kwah, M.X.-Y., Liu, C., Ma, Z., Shanmugam, M. K., Ding, L., et al. (2021). Resveratrol for cancer therapy: Challenges and future perspectives. Cancer Letters, 515, 63–72.

Article  CAS  PubMed  Google Scholar 

Jiang, Z., Chen, K., Cheng, L., Yan, B., Qian, W., Cao, J., et al. (2017). Resveratrol and cancer treatment: Updates. Annals of the New York Academy of Sciences, 1403(1), 59–69.

Article